Revenue
No reported data
Immix Biopharma, Inc. (IMMX)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $16.3M | $11.3M | $8.7M | $4.2M | $126,527 | $248,149 |
| Operating expenses | $30.0M | $22.7M | $16.1M | $8.2M | $1.4M | $453,852 |
| Operating income | −$30.0M | −$22.7M | −$16.1M | −$8.2M | −$1.4M | −$453,852 |
| Net income | −$29.4M | −$21.6M | −$15.4M | −$8.2M | −$24.4M | −$1.1M |
| Basic EPSper diluted share | -$0.89 | -$0.76 | -$0.89 | -$0.59 | -$6.64 | -$0.34 |
| Diluted EPSper diluted share | -$0.89 | -$0.76 | -$0.89 | -$0.59 | -$6.64 | -$0.34 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 10, 2025Form 4 | Rachman Ilya MCEO and Chairman | BuyCommon Stock | 746 | $6.67 | $5.0K | 1.14M |
| Dec 10, 2025Form 4 | Morris Gabriel SCFO | BuyCommon Stock | 770 | $6.58 | $5.1K | 291.4K |
| Sep 17, 2025Form 4 | Rachman Ilya MCEO and Chairman | BuyCommon Stock | 2.5K | $2.02 | $5.0K | 1.14M |
| Sep 16, 2025Form 4 | Morris Gabriel SCFO | BuyCommon Stock | 2.6K | $1.97 | $5.1K | 290.7K |
| Jun 18, 2025Form 4 | Rachman Ilya MCEO and Chairman | BuyCommon Stock | 2.2K | $2.30 | $5.0K | 1.14M |